Chronic obstructive pulmonary disease (COPD) is a disease that is typically progressive, and not fully reversible, with chronic and continuous respiratory symptoms. COPD is responsible for approximately 3 million deaths annually. The GOLD guidelines recommend a LAMA + LABA combination as initial therapy in patients with advanced disease (i.e., a predicted FEV1 of <30%). Triple therapy – a LAMA + LABA + an inhaled corticosteroid (ICS) – is recommended in patients who experience further exacerbation(s) on a LAMA + LABA combination. This program will review the recommendations for triple therapy and the evidence supporting these recommendations.